MXPA00004471A - Method and compositions for reducing dermatologicalaging and for reducing bruising - Google Patents

Abstract

Methods to reduce susceptibility to, severity or duration of, bruising of skin and topical compositions for practicing such methods. The topical compositionscomprise an isoflavonoid and a vehicle. The invention also includes a synergistic topical composition that includes, in addition to the isoflavonoid and vehicle, secondary components selected from specific classes of compounds.

Description

METHOD AND COMPOSITIONS TO REDUCE AGING DERMATOLOGICAL AND TO REDUCE CONTUSIONS 1. Field of the Invention The present invention relates to topical compositions and methods using same, for the total improvement of dermatological health. The present invention also relates to compositions for reducing susceptibility to contusions and for decreasing the healing time for bruises. which occur and to methods for using these compositions. The present invention also relates to topical compositions for alleviating the dermatological symptoms associated with hormonal aging and methods for using same. 2. Description of the Prior Art Skin aging results from the synergistic effects of intrinsic aging (due to age and genetic factors), photo-aging (due to exposure to ultraviolet rays), and, in women, to REF: 119717 hormonal aging (due to estrogen deficiency in peri-enopausal and menopausal women). Such dermatological aging manifests as wrinkles on the skin, pigmentation / age spots, pale skin, loosening of the skin, thinning of the skin, a decrease in elasticity and resilience. One cause of the aforementioned manifestations of dermatological aging is a pure loss of the collagen fibers in the skin. This pure loss of collagen fibers in the skin results in thinning of the dermis. Because the dermis acts to "decrease" the force of impact, this decrease in the thickness of the dermis can result in increased contusions.

In addition, some women also experience an increase in acne, due to these hormonal changes.

There is a need for a composition and method that will retard or reverse the negative dermatological effects associated with hormonal aging. There is a further need for a composition and method that will encompass the aforementioned with minimal adverse effects.

PCT Publication WO 98/21946 by Wurt an et al. (description of which is incorporated herein by reference), provides dietary supplements that include phytoestrogen compounds, and either (a) repair or therapeutic carbohydrates, (b) choline compounds or (c) both.

Publication WO 98/56373 by Gorbach (description of which is incorporated herein by reference) provides topical compositions using purified isoflavonoids, such as genistein, daidzein, biocanin A, formononet ina, O-demethylangolensin, glycitin, and equol. it also provides topical compositions that have between 1 and 40 mg of purified isoflavones per gram of base (ie, 0.1 wt% up to 4 wt%) to treat and prevent wrinkles Gorbach defines "pure isoflavonoids" as a Isoflavonoid in a more concentrated form than occurs in plants.

U.S. Patent No. 5,166,132 by Gordon, provides topical compositions having an improved modified enzyme casein solution, which are employed for the healing and relief of contusions.

BRIEF DESCRIPTION OF THE INVENTION It is an object of the present invention to provide topical compositions and methods for reducing dermatological aging.

It is another object of the present invention to provide topical compositions and methods to reduce susceptibility to contusions.

It is furthermore an object of the present invention to provide compositions and methods to reduce the severity and healing period for manifesting bruises.

DETAILED DESCRIPTION OF THE INVENTION A "topical composition" as used herein, refers to a composition proposed to be applied or spread directly on the surface of the skin. An "effective amount" means an amount of a compound or composition sufficient to induce a positive change in skin condition. A "physiologically acceptable vehicle" or a "suitable topical vehicle" refers to a drug, cosmetic, medicament or inert ingredient that is suitable for use in direct contact with human tissue without undue toxicity. All percentages refer to percentage by weight, based on the total weight of the topical composition.

The first principal component of the present invention is a fi xextract. The phytoextract is preferably a trógeno and, more preferably, either one (1) isoflavone, (2) steroidal, (3) sterol, (4) cumestan, (5) lignan, or (6) any mixture thereof.

The term "phytoextract" as used herein, encompasses all compounds that originate naturally in plants, although whether the present compound used in the present invention is extracted from a plant source or is man-made . As stated above, it is preferred that the phytoextract be a phytoestrogen. Preferably, the phytoextract is derived from a plant source. In the most preferred embodiment, the phytoextract is a phytoestrogen that is naturally derived. Alternatively, the phytoextract may be synthetically derived. "Phytoestrogen" as used herein, refers to compounds that are either (a) known to exhibit an estrogen-like effect or (b) specifically disclosed herein as a phytoestrogen.

The exemplary phytoextracts and their sources are shown below in Table 1.

TABLE 1 The most preferable phytoextracts are trogenic phytoes, such as daidzein, daidzin, acetyl daidzin, malonyl daidzin, glycitin, acetyl glycitin, malonyl glycitin, glycitein, genistin, acetyl genistin, malonyl genistin, genistein, equol, and any mixture thereof. . The most preferred phytoextracts are, daidzein, glycitein, genistein, equol and any mixture thereof. When the phytoextract is daidzein, glycitein, genistein, equol and any mixture thereof, the topical composition preferably comprises from about 0.01% to about 0.1% by weight of phytoextract, more preferably from about 0.015% by weight to about 0.08% by weight of phytoextract, and more preferably from about 0.02% by weight to about 0.072% by weight of phytoextract.

Examples of preferred plant sources include soybeans, soybeans, red clover, pomegranate, saw palmetto, canola and any mixture thereof.

In addition to the phytoextract component, the present invention preferably includes a secondary component. The secondary component is selected from one or more of the following twelve groups. 1. A compound that stimulates estrogen synthetase: Examples of such compounds include caffeine and / or derivatives thereof, and any mixture thereof. Caffeine is the most preferred of such compounds. 2. A compound capable of inhibiting the activity of alpha-reductase 5: Examples of such a compound include, linolenic acid, linoleic acid, finasteride, and any mixture thereof. 3. An exfoliation promoting compound: Suitable examples include alpha hydroxy acids; beta hydroxy acids; oxyacids, as described in U.S. Patent No. 5,847,003 (description of which is incorporated herein by reference); oxadiazides, as described in US Pat. No. 5,834,513 (description of which is incorporated herein by reference); compounds for mechanical exfoliation, such as bamboo exfoliating extract; salicylic acid; benzoyl peroxide; Alpha-keto acids; such as pyruvic acid, 2-oxopropanoic acid, acid 2-oxobutanoic, and 2-oxopentanoic acid; and any mixture thereof.

Preferred compounds, exfoliation promoters are lactic acid, glycolic acid, 3, 6, 9-trioxaundecandioic acid, and any mixture thereof. When the present invention includes an exfoliation promoting compound, the composition comprises about 1% by weight up to 20% by weight, preferably 1% by weight up to about 15% by weight, more preferably, about 4% by weight, up to about 10% by weight. % by weight of acid, and more preferably 4% by weight, of the exfoliating promoter compound. 4. A sunscreen agent / protector of ultraviolet (UV) light: Examples include organic and inorganic sunscreens, such as titanium dioxide, zinc dioxide, methylbenzylidene camphor and / or its derivatives, octocrylene, anthranilates, benzophenones, butyl ethoxydibenzoylmethane (avobenzone), naphtholsulfonates, benzoic acid derivatives, salicylates, cinnamic acid derivatives, and mixtures thereof . Of these, butylmethoxydibenzoylmethane (PARSOL 1789), octocrylene, octylsalicylate, octylmethoxymamate and oxylbenzone, and mixtures thereof, are preferred. Butylmethoxydibenzoi lmetan or avobenzone (PARSOL 1789), oxybenzone and octyl methoxycinnamate, and mixtures thereof, are more preferred. In addition, US Pat. No. 5,824,702 by Wei (description of which is incorporated herein by reference), provides that genistein exhibits protective activity against photodamage and skin cancer induced by ultraviolet light. The co-formulation with a sunscreen agent / ultraviolet light protector is particularly desirable when the present invention is prepared for consumers who engage in outdoor activities.

Retinoids: Examples of suitable retinoids include: retinol, retinoic acid, retinyl palmitate, retinyl propionate, retinyl acetate, isotetrinoin, also as synthetic mimic retinoids, and derivatives of the aforementioned.

Hirsutism inhibiting agents: Examples of such agents include α-linolenic acid, linoleic acid, and derivatives thereof.

Barrier-function-increasing agents: Examples include ceramides, essential fatty acids and their esters, especially glycerides, α-hydroxy fatty acids and their esters derived with alkanols through hydroxyl carboxylic or with other omega-hydroxyl fatty acids, last type is more preferred, with phospholipids, cholesterol and its esters, such as cholesteryl hemisuccinate, and cholesteryl phosphate of which, cholesterol phosphate and fatty acids are more preferred, cholestanol and its derivatives. The barrier enhancing agent may be added to a topical composition either as singular molecular entities or as a complex mixture of lipids derived from either plant, animal, or synthetic sources.

Collagen-increasing agents: These agents prevent the weakening of the skin by promoting pure increase in collagen, either by reducing the breakdown of collagen or by promoting the formation of collagen. Examples of such inhibitors include Cl ara extract (Soph ora augus ti foli a), ascorbyl phosphoryl cholesterol, ascorbic acid, ascorbic acid derivatives and any mixture thereof. 9. Elastase inhibitors: Examples of these inhibitors include Honeysuckle extract. { Loni wax caprifoli um). These inhibitors act to prevent the weakening of the skin.

. Skin brightening agents: Examples include kojic acid, hydroquinone, sweet stick or licorice derivatives, ascorbic acid / ascorbic acid derivatives (eg, magnesium ascorbyl phosphate), arbutin, bearberry. { Taphyl ions (uva ursi), Glycyrrhi za gl abra and its derivatives, Chl orel l a vulgar s extract, and any mixture thereof. 1. Antioxidants: Examples include compounds having phenolic hydroxy functions, such as ascorbic acid, ascorbic acid derivatives, gallic acid derivatives (for example propylgalate); ferulic acid derivatives (e.g., ethyl ferulate, sodium ferulate); nitrones; N-terbutil-ni trona; I- (4-pyridyl-1-oxido) -N-tert-butyl-nitrone; curcumin, tetrahydrocurcumin, 6-hydroxy-2, 5, 7-tetramethylchroman-2-carboxylic acid, uric acid; reductive acid; tannic acid, rosmarinic acid, tocopherol and its derivatives; catechins, and any mixture thereof. Other suitable antioxidants are those having one or more thiol functions (-SH), in either the reduced or non-reduced form, such as glutathione, lipoic acid, thioglycolic acid, and other sulfhydryl compounds. The antioxidant may be inorganic, such as sulfites, bisulfites, metabisulfites, or other inorganic salts and sulfur-containing acids.

Skin refreshing compounds: Examples include entol, methyl glycerol, asymmetric carbonates, thiocarbonates and urethanes, N-substituted carboxamides, ureas or phosphine oxides, methyl illate, menthone glycerin acetal, and any mixture thereof. Since many women experience "sudden access of heat / redness during perimenopause, co-formulation with skin refreshing compounds, it is particularly desirable when topical compositions of the present invention are provided for such women." The secondary component increases the dermatological benefits achieved. It is more preferable that the compositions of the present invention include at least two secondary components with each component selected from a different group, Table 2 below shows examples of such preferred combinations.

TABLE 2 Examples of combinations of phytoestrogens with a secondary component The compositions of the present invention may include other cosmetic and pharmaceutical excipients and excipients. Such suitable cosmetic and pharmaceutical agents include, but are not limited to, anti-fungal, vitamins, anti-inflammatory, anti-microbial, analgesic, nitric oxide synthase inhibitors, insect repellents, self-tanning agents, surface activators. , humidifiers, stabilizers, preservatives, antiseptics, thickeners, lubricants, humectants, chelating agents, penetration enhancers in the skin, emollients, fragrances and dyes.

Examples of suitable thickening agents include xanthan gum, hydroxypropylcellulose, hydroxyethylcellulose, carbomer, acacia gum, Seppigel 305 (available from Seppic Co., France), and aluminum magnesium silicate.

The topical compositions of the present invention may include, and their utility may be increased by, humectants, such as urea, pyrrolidone, carboxylic acid, amino acids, sodium hyaluronate, certain polyols and other compounds with hygroscopic properties.

The compositions of the present invention can also include one or more of the following: (i) vitamins, such as vitamin B; 1,25-hydroxyvitamin D3; vitamin K, tocopherol and its derivatives; tocotrienols and their derivatives; nicotinic acid and its esters, pantothenic acid and its esters, panthenol, folic acid and its derivatives; phytic acid; ascorbic acid and its derivatives; vitamin A and its derivatives; and any mixture thereof; (ii) anti-fungi, such as tolnaftate and ketoconazole; (iii) self-tanning agents, such as dihydroxyacetone and lawsona; (iv) anti-microbial agents, such as erythromycin and tetracycline; (v) topical analgesics, such as lidocaine, benzocaine, butacaine, tetracaine, spice oil and eugenol; (vi) anti-inflammatory agents, can be included in topical compositions of the present invention. These anti-inflammatory agents are used at concentrations of about 0.025% by weight to about 10% by weight, preferably, from about 0.5% by weight to about 1% by weight, with the anti-inflammatory concentration adjusted up or down depending of the potency of the agents used. Examples include hydrocort isone, prednisone, prednisolone, aspirin, aspirin derivatives, aloe vera, willow bark, chamomilla, and mixtures thereof; (vii) nitric oxide synthase inhibitors that reduce redness of the skin, vasodilation and inflammatory reactions, especially in response to electromagnetic radiation or ionization or the action of chemically or biochemically aggressive compounds, can be included in this invention. Nitric oxide synthase inhibitors are more preferably selected from the group including guanidine derivatives, especially monoaminoguanidine and methylguanidine, L-arginine derivatives, especially NG-nitro-L-arginine and their esters, NG-monomethyl-L-arginine. , 2-iminopiperidines, asymmetric dimethylarginine (ADMA), boronic acid analog of L-arginine (Boroarg-OH- • 2HC1), and other 2-iminoazaheterocyclics; (viii) insect repellents, such as aliphatic, cyclic or aromatic amides, citronella oil, terpineol, cineole, neem oil, terephthalic acid and its esters, ethyl butylacetylaminopropionate and N, -diethyl-m-toluamide (DEET), They can be included in the present invention. Co-formulation with insect repellents may be particularly desirable when the present invention is used to prevent contusions. For those who engage in vigorous outdoor activities, such as hiking and other sports, which have an insect repellent incorporated in the present invention, they provide a convenient two-in-one preventive measure.

The carrier may comprise more conventional emollients including mineral oil, petrolatum, paraffin, ceresin ozokerite, microcrystalline wax, dimethyl polysiloxanes perhydrosqualenes, methylphenyl polysiloxanes, silicone-glycol copolymers, triglyceride esters, acetylated monoglycerides, ethoxylated glycerides, alkyl acid esters fatty acids, fatty acids and alcohols, lanolin, lanolin derivatives, polyhydric alcohol esters, sterols, beeswax derivatives, polyhydric alcohols and polyethers, and fatty acid amides.

The emulsifiers may be cationic, anionic, nonionic, amphoteric, or a combination thereof. Nonionic emulsifiers are preferred. The non-ionic exemplifying e? Uctors are sorbitans, commercially available, alkoxylated fatty alcohols and alkyl polyglycosyls. Anionic emulsifiers may include soaps, alkyl sulfates, monoalkyl, and dialkyl phosphates, alkyl sulfonates and acyl isothionates.

Suitable condoms for use with the present compositions include alkanols, especially ethanol and benzyl alcohol, parabens, sorbates, benzoic acid / benzoates, urea derivatives and isothiazolinones.

The general activity and softness to the skin of the present topical compositions can also be increased by neutralization at pH from about 3.5 to about 7.0, more preferably from about pH 3.7 to about 5.6, with one or more of the ammonium hydroxides, hydroxide of potassium, sodium hydroxide, arginine or other amino acids, and / or triethanolamines.

The usefulness of the present topical compositions can also be increased by certain chelating agents incorporated in the composition at levels from about 0.01% to about 25% by weight, more preferably from about 0.5% to 10%, and more preferably from about 1% up to approximately 5%. Suitable examples of the chelating agents include those having a high affinity for zinc, calcium, magnesium, iron and / or copper ions, such as ethylene diamine tetra-acetic acid.

The topical compositions of the present invention can be further formulated in accordance with methods known in the art to provide cosmetic compositions such as emulsions, gels, creams, lotions, ointments, pastes, adhesives, coatings, pencils, essences and serums, as well as other topical cosmetic vehicles. It is also contemplated that the topical compositions of the present invention may be incorporated into delivery systems such as liposomes and topical patches, tapes and sprays.

The topical compositions of the present invention are employed for the improvement of the aesthetic appearance of the skin by any one of the following methods. 1. Reduce dermatological aging, particularly dermatological aging due to hormonal aging; 2. Decrease the fragility of the skin; 3. Prevent and reverse the loss of collagen; 4. Prevent skin atrophy; 5. Promote / accelerate cell movement; 6. Provide cushioning to blood vessels; 7. Improvement of the texture of the skin; 8. Decrease fine lines and wrinkles; 9. Improvement of skin tone; 10. Increase the thickness of the skin; 11. Decrease the size of the pores; 12. Minimization of skin discoloration; 15 13. Restoration of the luster or shine of the skin; 14. Minimization of signs of fatigue; 15. Reduce acne; 16. Decrease susceptibility to bruises; and 17. Decrease the severity of contusions; 18. Decrease the time required for the healing of bruises.

The present invention also includes methods by which these compounds can be used to address the skin conditions mentioned above. Such methods include topically applying an effective amount of the composition of the present invention to areas of the foot., typically once or twice daily. When the present invention is used to improve the overall aesthetic appearance of the skin, preferred areas of application include the face and areas of the neck. When the present invention is used to reduce the susceptibility, severity and healing time of bruises, the preferred areas of application include hands, arms (particularly, forearm), legs (particularly lower areas of the leg), hip and any other area subject to impact.

- EXAMPLE 1 Thirty-seven women participated in a twelve-week clinical study to evaluate the efficacy of a topical composition, Sample A, an increase in the thickness of the skin. The woman was treated on a forearm with a trial product for twelve weeks. The arm to be treated (left or right) was randomly assigned as the test area. The treatment was once during the morning and sample A was applied to the treated area SAMPLE A Ingredients by weight Lactic acid (85%) 4.71 Soy extract (0.081 25.00 Vehicle c.

The skin was then visually assessed at four weeks and eight weeks. The visual improvements of the treated arm were very evident. After four weeks, the skin looked and felt softer. The skin also seemed brighter. At eight weeks, the pigment discolorations had a brighter appearance, and the skin had a much better overall appearance. If the treated skin was compressed laterally, the treated skin was much more resistant to compression. Untreated skin easily compressed, resulting in visible wrinkling.

It is believed that the resistance to compression presented by the treated skin was the result of the epidermis and the dermis becoming "bumpy" or thickened. The resulting increase in thickness is believed to have resulted from the activity of lactic acid, soy extract or the combination of two materials.

EXAMPLE 2 Since the skin thickening provides more "cushioning", which could result in fewer bruises from an impact or sting, the following twelve week study was performed to determine the effectiveness of the present invention to reduce susceptibility. from skin to contusions.

The assay used Sample A as discussed above. Fifteen of the thirty-seven women who participated in the trial discussed in Example 1 above, have had their arms contusions at twelve-week exposed time. All these women were post-menopausal.

The volar forearm was bruised using a pricking method. The skin was given a calibrated picket using Lange Skinfold Calipers. Both volar, treated and untreated forearms were punctured approximately two inches from the flexion region of the elbow.

The woman returned to the laboratory at day one, four days and seven days after the bruises. The L-a-b measurements by Minolta chromameter (a skin color measurement target) were taken before the bruises and in the post-contusions after the days. Each woman also completed a self-assessment questionnaire on the evaluation days.

Four days after the bruises were selected as the best day for the assessment of contusions. Not all bruises appeared on the first day after the bruises, but all bruises appeared within four days of the trauma. In addition, of those contusions that appeared early (a day after the trauma), some were completely resolved seven days later. Therefore, the fourth day after the contusion, was selected as the best point in time, to assess the contusions.

Measurement of Color L-a-b of the contusions Measurements were made in the chromameter, in the L-a-b mode, evaluating three color components of the color of the contusions. The "L" value is a light / dark rating. The "a" value is a red / green rating. The "b" value is a yellow / blue rating. The following are the average changes of the line values. of base (normal skin color), obtained by "L", "a" and "b".

Change of baseline values - 4 days after the bruises Treaty Not treated L (light) -1.1 -2.9 a (red) 0.26 2.02 b (yellow) 1.7 2.8 The highest value, "L" illuminator of the skin. Therefore, untreated bruised skin darkened more (or bruised more) that the skin increased with more reddish. The untreated bruises were redder than the bruises treated. The yellow component of the contusion, the "b" value, is more yellow with a larger number. The "b" value can also be a blue measure, however, the highest values obtained were in the yellow (positive) range of the scale. The average value "b" for untreated skin was greater for untreated skin than for treated skin.

Most of the panelists have reduced bruising in the treated arm. The following diagrams show the number of panelists with better "L" (illuminator), "a" (less red), or [less yellow] values for the treated and untreated arm: Number of Panelists with Better Values. - Days 4 After the contusions Treaty Not treated Illuminator (L) 11 4 Less ro or (a) 10 5 Less yellow (b) 11 4 The tables with individual data for "L", (Table 3), "a" (Table 4) and "b" (Table 5), are shown below.

TABLE 3 Change of the baseline in the "L" value (Dark contusion) - Days 4 after the contusion Note: The upper value "L", the illuminator of the skin.

TABLE 4 Change of the baseline in the value days after the bruises upper indicates that the skin is oj iza TABLE 5 Change of the baseline in the "b" value 4 days after the contusions Note: the upper value "b" indicates that the skin is more yellow.

The data clearly suggest that daily use of a product, such as Sample A, can help reduce susceptibility to bruising. Contusions may still originate, but may be less severe.

Various modifications and alterations to the present invention can be appreciated, based on a review of this application. These changes and additions will be proposed within the scope and spirit of the present invention as defined by the following claims.

It is noted that in relation to this date, the best method known by the applicant to carry out the aforementioned invention, is that which is clear from the present description of the invention.

Claims (27)

1. CLAIMS Having described the invention as above, the content of the following is claimed as property. 1. A method to reduce the susceptibility to, severity or duration of contusions, characterized in that it comprises, application of a topical composition comprising a phytoextract and a vehicle.
2. 2. The method according to claim 1, characterized in that the phytoextract is a phytoestrogen.
3. 3. The method according to claim 2, characterized in that the phytoestrogen is selected from the group consisting of isoflavones, steroids, sterols, cumestane, lignans, and any mixture thereof. 4 - . 4 - The method according to claim 1, characterized in that the phytoextract is selected from the group consisting of: daidzein, daidzin, acetyl daidzin, malonyldaidzin, glycitin, acetyl glycitin, malonyl glycitin, glycitein, genistin, acetyl genistin, malonil genistin, genistein, equol and any mixture thereof. 5. The method according to claim 1, characterized in that the phytoextract is about 0.01% by weight to about 0.1% by weight of the topical composition. 6. The method according to claim 1, characterized in that the topical composition further comprises a secondary component, selected from the group consisting of: (i) a compound stimulating the estrogen synthetase; (ii) a compound capable of inhibiting the activity of alpha-reductase 5; (iii) an exfoliation promoting compound; (iv) a sunscreen agent / ultraviolet light (UV) protector; (v) a retinoid; (vi) an inhibiting agent of hirsutism; (vii.) an agent that increases the barrier function; (viii) a collagen-increasing agent; (ix) an elastase inhibitor; (x) an illuminating agent of the skin; (xi) an antioxidant; (xii) a skin refreshing agent; (xii) any mixture thereof; 7. The method according to claim 6, characterized in that the secondary component is the exfoliation promoter compound, selected from the group consisting of fa-hydroxy acids, β-hydroxy acids, keto acids, oxacids, oxadiazides, derivatives thereof, and any mixture thereof. 8. The method according to claim 6, characterized in that the exfoliating promoter compound is selected from the group consisting of: lactic acid, glycolic acid; 3, 6, 9-ttrioxaundecandioic acid, and any mixture thereof. 9. The method according to claim 6, characterized in that the topical composition comprises two or more secondary components, and each of the secondary components is selected from a different group of said secondary components. 10. The method according to claim 6, characterized in that the topical composition additionally comprises a tertiary component selected from the group consisting of anti-fungal, vitamin, anti-inflammatory, antimicrobial, analgesic, nitric oxide synthase inhibitors, insect repellents, self-tanning agents, surfactants, humidifiers, stabilizers, preservatives, antiseptics, thickeners, lubricants, humectants, guelantes agents, skin penetration enhancers, emollients, fragrances, dyes and any mixture thereof. 11. The method according to claim 1, characterized in that the method includes applying the topical composition twice daily. 12. The method according to claim 1, characterized in that the vehicle is selected from the group consisting of: solid, solution, essence, serum, pencil, atomizer, lotion, emulsion, cream, microemulsion, gel, ointment, patch, tape , and dust. 13. A method for reducing the susceptibility to, the severity or duration of contusions in perimenopausal or menopausal women, characterized in that it comprises applying a topical composition comprising u? phytoestrogen and a vehicle. 14. A method for improving the aesthetic appearance of the skin, characterized in that it comprises topically applying a composition comprising a phytoestrogen and a vehicle. fifteen . The method according to claim 14, characterized in that the f-toestrogen comprises from about 0. 01% by weight up to about 0. 08% in weight of the topical composition. 16. The method according to claim 15, characterized in that the phytoestrogen is selected from the group consisting of: daidzein, daidzin, acetyl daidzin, malonyldaidzin, glycitin, acetyl glycitin, malonyl glycitin, glycitein, genistin, acetyl genistin, malonyl genistin, genistein, equol and any mixture thereof. 17. The method according to claim 14, characterized in that the topical composition additionally comprises a secondary ingredient selected from the group consisting of: (i) an estrogen synthetase stimulating compound; (ii) a compound capable of inhibiting the activity of al-fa-reductase 5; (iii) an exfoliation promoting compound; (iv) a sunscreen agent / ultraviolet light (UV) protector; (v) a retinoid; (vi) an inhibiting agent of hirsutism; (vii) an agent that increases the barrier function; (viii) a collagen-increasing agent; (ix) an elastase inhibitor; (x) an illuminating agent of the skin; (xi) an antioxidant; (xii) a skin refreshing agent; (xiii) any mixture thereof; 18. The method according to claim 17, characterized in that the improvement in aesthetic appearance includes at least one of the following: a. Decrease the fragility of the foot. b. Prevent and reverse the loss of collagen; c. Prevent skin atrophy; d. Improvement of firmness / corpulence of the skin; e. Improved skin tone; F. Increase the thickness of the skin; and g. Decrease the size of the pores; 19, the method according to claim 14, characterized in that the improvement in the appearance is aesthetic includes one of the following: a. Reduce the aging of the skin, particularly dermatological aging due to hormonal aging; b. Decrease the fragility of the skin; c. Prevent and reverse the loss of collagen; d. Prevent skin atrophy; e. Promote / accelerate cell movement; F. Improvement of firmness / corpulence 10 of the skin; g. Improvement of the texture of the skin; h. Decrease fine lines and wrinkles; i. Improved skin tone; j. Increase the thickness of the skin; 15 k. Decrease the size of the pores; 1. Minimization of skin discoloration; m. Restoration of the luster or shine of the skin; 20 n. Mimicization of signs of fatigue; or. Reduce acne; The method according to claim 19, characterized in that the improvement in aesthetic appearance includes one of the following: a. Decrease the fragility of the skin; b. Prevent skin atrophy; c. Improvement of firmness / corpulence of the skin; e d. Increase in the thickness of the skin; 21. The method according to claim 19, characterized in that the vehicle is selected from the group consisting of a solid, solution, essence, serum, pencil, atomizer, lotion, emulsion, cream, microemulsion, gel, ointment, patch, tape and dust. 22. A topical composition, characterized in that it comprises: a. a phytoestrogen; b. A vehicle; and c. at least one secondary component selected from the group consisting of: (i) a compound stimulating the estrogen synthetase; (ii) a compound capable of inhibiting the activity of alpha-reductase 5; (iii) an exfoliation promoting compound; (iv) a sunscreen agent / ultraviolet light (UV) protector; (v) a retinoid; (vi) an inhibiting agent of hirsutism; (vii) an agent that increases the barrier function; (viii) a collagen-increasing agent; (ix) an elastase inhibitor; (x) an illuminating agent of the skin; (xi) an antioxidant; (xi) a skin refreshing agent; and (xiii) any mixture thereof;23. The topical composition according to claim 22, characterized in that at least one secondary component is selected from the group consisting of: (i) an exfoliation promoting compound; (ii) a sunscreen agent / ultraviolet light (UV) protector; (iii) a retinoid; (iv) an illuminating agent of the skin; (v) an antioxidant; (vi) a skin freshening agent; and (vii) any mixture thereof; 24. The topical composition according to claim 22, characterized in that at least one secondary component is selected from the group consisting of: A topical composition comprising: (i) an exfoliation promoting compound; (ii) a sunscreen agent / ultraviolet light (UV) protector; (iii) a retinoid; and (iv) any mixture thereof; 25. The topical composition according to claim 22, characterized in that at least one secondary component is selected from the group consisting of: (i) an exfoliation promoting compound; (ii) a sunscreen agent / ultraviolet light (UV) protector; (iii) an illuminating agent of the skin; and (iv) any mixture thereof; 26. The topical composition according to claim 22, characterized in that at least one secondary component is selected from the group consisting of: (i) a sunscreen / ultraviolet (UV) light protector; (ii) a retinoid; (iii) an illuminating agent of the skin; and (iv) any mixture thereof; 27. The topical composition according to claim 22, characterized in that at least one secondary component is selected from the group consisting of: (i) a sunscreen / ultraviolet (UV) light protector; (ii) a retinoid; (iii) a collagen enhancing agent; and (iv) any mixture thereof. DERMATOLOGICAL AND TO REDUCE CONTUSIONS SUMMARY OF THE INVENTION Methods to reduce the susceptibility to, severity or duration of, skin contusions and topical compositions to practice such methods. Topical compositions comprise an isoflavonoid and a carrier. The invention also includes a topical synergistic composition that includes, in addition to the isoflavonoid and the carrier, secondary components selected from a specific class of compounds.